Ghetu Alexandru F, Corcoran Connie M, Cerchietti Leandro, Bardwell Vivian J, Melnick Ari, Privé Gilbert G
Division of Cancer Genomics and Proteomics, Ontario Cancer Institute, 101 College Street, Toronto, ON M5G 1L7, Canada.
Mol Cell. 2008 Feb 15;29(3):384-91. doi: 10.1016/j.molcel.2007.12.026.
The transcriptional corepressors BCOR, SMRT, and NCoR are known to bind competitively to the BCL6 BTB domain despite the fact that BCOR has no detectable sequence similarity to the other two corepressors. We have identified a 17 residue motif from BCOR that binds directly to the BCL6 BTB domain and determined the crystal structure of the complex to a resolution of 2.6 A. Remarkably, the BCOR BCL6 binding domain (BCOR(BBD)) peptide binds in the same BCL6 binding site as the SMRT(BBD) peptide despite the lack of any significant sequence similarity between the two peptides. Mutations of critical BCOR(BBD) residues cause the disruption of the BCL6 corepression activities of BCOR, and a BCOR(BBD) peptide blocks BCL6-mediated transcriptional repression and kills lymphoma cells.
已知转录共抑制因子BCOR、SMRT和NCoR可竞争性结合BCL6的BTB结构域,尽管BCOR与其他两种共抑制因子没有可检测到的序列相似性。我们从BCOR中鉴定出一个17个残基的基序,它直接与BCL6的BTB结构域结合,并确定了复合物的晶体结构,分辨率为2.6埃。值得注意的是,尽管这两种肽之间缺乏任何显著的序列相似性,但BCOR BCL6结合结构域(BCOR(BBD))肽与SMRT(BBD)肽结合在相同的BCL6结合位点。BCOR(BBD)关键残基的突变会导致BCOR的BCL6共抑制活性被破坏,并且BCOR(BBD)肽会阻断BCL6介导的转录抑制并杀死淋巴瘤细胞。